Pharming Group (NASDAQ:PHAR) Short Interest Update

Pharming Group (NASDAQ:PHAR) was the target of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 25,500 shares, an increase of 165.6% from the October 31st total of 9,600 shares. Based on an average trading volume of 6,600 shares, the short-interest ratio is currently 3.9 days.

Wall Street Analyst Weigh In

PHAR has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research note on Thursday, October 24th. Oppenheimer lowered their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th.

Pharming Group Stock Down 3.0 %

Shares of NASDAQ PHAR traded down $0.23 during midday trading on Friday, hitting $7.35. The company’s stock had a trading volume of 5,887 shares, compared to its average volume of 5,064. The business’s fifty day simple moving average is $8.24 and its two-hundred day simple moving average is $8.24. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. Pharming Group has a 1 year low of $6.65 and a 1 year high of $13.20. The firm has a market capitalization of $498.55 million, a price-to-earnings ratio of -28.27 and a beta of 0.13.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC raised its position in Pharming Group (NASDAQ:PHAR) by 32.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.